日本肾脏病临床实践指南参与者的利益冲突评估
这项横断面研究评估了日本肾脏病学会慢性肾脏病指南全部142名作者在2016至2019年间的财务与非财务利益冲突,并分析了指南证据质量和利益冲突政策。结果显示125名作者(88%)共获得6,742,889美元个人付款,76%的推荐基于低或极低质量证据,美国、欧洲和日本均无完全严格透明的利益冲突政策。
要点
- 142名指南作者中125人(88%)获得56家药企个人付款,中位每作者8258美元。
- 861条参考文献中69条(8%)为作者自引,76%推荐基于低或极低质量证据。
- 美国、欧洲和日本均无完全严格透明的肾脏病指南作者利益冲突政策。
核心结论
- 日本慢性肾脏病指南多数推荐基于低质量证据,且作者与药企存在财务关联,提示需要更好的财务利益冲突管理。
研究设计与样本
- 横断面研究,纳入日本肾脏病学会慢性肾脏病指南全部142名作者,使用2016至2019年日本92家主要制药公司的个人付款数据库及作者自引数据,并评估指南证据质量、推荐强度及日本、美国、欧洲肾脏病学会的利益冲突政策。
主要发现
- 142名作者中125名(88%)在2016至2019年间从56家制药公司获得共6,742,889美元个人付款。
- 每作者四年合并付款中位数为8258美元(四分位距2230至51,617美元)。
- 指南制定期间及之后,付款金额和获得付款的作者比例保持稳定。
- 主席、副主席和组长获得的个人付款高于其他指南作者。
- 指南861条参考文献中69条(8%)为作者自引,76%的推荐基于低或极低质量证据。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Rigorous and transparent management strategies for conflicts of interest and clinical practice guidelines with the best available evidence are necessary for the development of nephrology guidelines. However, there was no study assessing financial and nonfinancial conflicts of interest, quality of evidence underlying the Japanese guidelines for CKD, and conflict of interest policies for guideline development. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This cross-sectional study examined financial and nonfinancial conflicts of interest among all 142 authors of CKD guidelines issued by the Japanese Society of Nephrology using a personal payment database from all 92 major Japanese pharmaceutical companies between 2016 and 2019 and self-citations by guideline authors. Also, the quality of evidence and strength of recommendations underlying the guidelines and conflicts of interest policies of Japanese, US, and European nephrology societies were evaluated. RESULTS: Among 142 authors, 125 authors (88%) received $6,742,889 in personal payments from 56 pharmaceutical companies between 2016 and 2019. Four-year combined median payment per author was $8258 (interquartile range, $2230‒$51,617). The amounts of payments and proportion of guideline authors with payments remained stable during and after guideline development. The chairperson, vice chairperson, and group leaders received higher personal payments than other guideline authors. Of 861 references in the guidelines, 69 (8%) references were self-cited by the guideline authors, and 76% of the recommendations were on the basis of low or very low quality of evidence. There were no fully rigorous and transparent conflicts of interest policies for nephrology guideline authors in the United States, Europe, and Japan. CONCLUSIONS: Most of the Japanese CKD guideline recommendations were on the basis of low quality of evidence by the guideline authors tied with pharmaceutical companies, suggesting the need for better financial conflicts of interest management.
引用
- Murayama A, Yamada K, Yoshida M, et al. Evaluation of Conflicts of Interest among Participants of the Japanese Nephrology Clinical Practice Guideline. Clin J Am Soc Nephrol. 2022. PMID: 35623883. doi:10.2215/CJN.14661121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。